<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Allergan Receives FDA Approval for Migraine Treatment
Image Overlay - Allergan Receives FDA Approval for Migraine Treatment

Allergan Receives FDA Approval for Migraine Treatment

Allergan Receives FDA Approval for Migraine Treatment

UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks. The therapy is taken by the user once a migraine starts — UBRELVY then provides relief for up to 24 hours. Yourway supports a patient-centric supply chain so that drugs in clinical trials can reach patients faster, regardless of where they are located.

Back to Index
Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit (Munich)

April 15-16, 2024
Science Congress Center Munich

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Media

Articles

The At-home Trial Experience: Leveraging value-chain to reach and retain patients

Open chat
Come chat with us!
Hello! How can I help you?